Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 9/20 | 0.39 |
| ▸ | PTGES | O14684 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16599587 | 0.75 | NPC1 (0.44) | NPC1RAB9ABRD4KDM4EMAPT | |
| SCHEMBL16599502 | 0.75 | BRD4 (0.37) | NPC1RAB9ABRD4PTGESKDM4E | |
| SCHEMBL20203104 | 0.69 | BRD4 (0.45) | NPC1RAB9ABRD4PTGESMAPT | |
| SCHEMBL24463149 | 0.68 | ALDH1A1 (0.39) | NPC1RAB9ABRD4MAPTPARP1 | |
| SCHEMBL16599668 | 0.66 | NPC1 (0.50) | NPC1RAB9AKDM4EMAPTGFER | |
| SCHEMBL22497700 | 0.66 | MAPT (0.40) | NPC1RAB9ABRD4PTGESKDM4E | |
| SCHEMBL17342640 | 0.66 | NPC1 (0.53) | NPC1RAB9ABRD4PTGESKDM4E | |
| SCHEMBL13907882 | 0.65 | NPC1 (0.49) | NPC1RAB9ABRD4MAPT | |
| SCHEMBL6756279 | 0.65 | NPC1 (0.52) | NPC1RAB9AKDM4EMAPTGFER | |
| SCHEMBL18152745 | 0.64 | CYP1A2 (0.43) | NPC1RAB9ABRD4MAPTPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160280688-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-29 | — | — | US | disclosed |
| US-20160280688-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-29 | — | — | US | disclosed |
| US-20160280688-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-29 | — | — | US | disclosed |
| WO-2015044174-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES AS MODULATORS OF FACTOR XIA | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280688-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES | PAH, PEPD, AADAT | NPC1 4114/4885RAB9A 3497/4885BRD4 2577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.